<DOC>
	<DOCNO>NCT01508195</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence fix dose combination ( FDC ) tablets canagliflozin metformin immediate release ( IR ) comparison individual component FDC tablet ( canagliflozin metformin IR ) .</brief_summary>
	<brief_title>A Study Canagliflozin Metformin Immediate Release ( 50 mg/500 mg ) FDC Tablets Healthy Volunteers</brief_title>
	<detailed_description>This open-label ( identity study drug know volunteer study staff ) , single-center study evaluate bioequivalence ( see blood level one drug equivalent blood level another drug ) canagliflozin metformin IR administer orally ( mouth ) individual component ( ie , separate tablet canagliflozin metformin IR ) ( Treatment A ) administer FDC tablet ( ie , canagliflozin metformin IR contain tablet ) ( Treatment B ) . Healthy volunteer participate study randomly ( chance ) assign receive single dose Treatment A follow single dose Treatment B Treatment B follow Treatment A washout period approximately 15 day treatment . The total duration study approximately 51 day .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Body mass index ( BMI ) 18.5 30 kg/mÂ² ( inclusive ) body weight less 50 kg History current medical illness , abnormal value hematology clinical chemistry laboratory test , abnormal physical examination , vital sign 12lead ECG deem clinically significant Investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Metformin IR</keyword>
</DOC>